Viewing Study NCT06952660

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:11 AM
Ignite Modification Date: 2026-07-10 @ 5:57 PM
Study NCT ID: NCT06952660
Status: RECRUITING
Last Update Posted: 2025-12-12
First Post: 2025-04-15
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
Sponsor: Pfizer
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Cervical Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Uterine Neoplasms View
None Genital Neoplasms View
None Female Urogenital Neoplasms View
None Neoplasms by Site View
None Neoplasms Uterine View
None Cervical Diseases View
None Uterine Diseases View
None Genital Diseases, Female View
None Female Urogenital Diseases View
None Female Urogenital Diseases and Pregnancy Complications View
None Urogenital Diseases View
None Genital Diseases Uterine Cervical Neoplasms, View
None Tisotumab vedotin View